Papillary thyroid cancer organoids harboring BRAF V600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies.

Dong ChenXi SuLizhang ZhuHao JiaBin HanHaibo ChenQingzhuang LiangChenchen HuHao YangLisa LiuPeng LiWei WeiYongsheng Zhao

Published in: Journal of translational medicine (2023)

These data indicate that patient-derived PTC organoids may be a powerful research tool to investigate tumor biology and drug responsiveness, thus being useful to validate or discover targeted drug combinations.

Keyphrases

papillary thyroid
lymph node metastasis
metastatic colorectal cancer
wild type
adverse drug
electronic health record
squamous cell carcinoma
cancer therapy
genome wide
single cell
induced pluripotent stem cells
machine learning
drug delivery